IL-13 blockade with a humanized monoclonal antibody RPC4046 significantly reduces esophageal eosinophilia and endoscopic features in EoE patients and also improves dysphagia; however, the effect is more prominent in steroid refractory EoE patients, suggesting that severe subjects may do well with anti-IL-13 therapy (139). Here, IL13 is linked to eosinophilic esophagitis.